Effect of COVID-19 convalescent plasma produced by HEMOPE: A randomized study, with a comparative group in several centers

Phase 3

• Conditions: Diabetes Mellitus; Hypertension; Lung Diseases; Respiratory Insufficiency; Respiration, Artificial; Critical Care; Hospitalization; C18.452.394.750; C14.907.489; C08.381

• Registration Number: RBR-7jqpnw
• Lead Sponsor: niversidade de Pernambuco

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-29
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

adults> 18 years with diagnosis of COVID – 19, who are hospitalized; and considered as having a condition that increases the risk of a worse prognosis: obesity; diabetes mellitus (DM); systemic arterial hypertension (SAH); chronic lung disease, obesity, diseases that alter immunity (AIDS, neoplasms or autoimmune diseases in immunosuppressive therapy, chronic liver disease.

Exclusion Criteria

History of anaphylactic reaction related to blood transfusion.

Study & Design

• Study Type: Intervention
• Study Design: Not specified